<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104269">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01979861</url>
  </required_header>
  <id_info>
    <org_study_id>SE-3000</org_study_id>
    <nct_id>NCT01979861</nct_id>
  </id_info>
  <brief_title>Safety &amp; Effectiveness Study of AEGEA Vapor System to Treat Excessive Uterine Bleeding</brief_title>
  <official_title>A Prospective, Multicenter, Clinical Trial to Evaluate the Safety and Effectiveness of the AEGEA Vapor System for the Treatment of Excessive Uterine Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegea Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aegea Medical, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the AEGEA Vapor System for endometrial ablation
      is safe and effective for reducing menstrual blood loss in women with excessive uterine
      bleeding (menorrhagia)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction of menstrual blood loss</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Device or procedure related SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoint</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of Life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>vapor endometrial ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>endometrial ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AEGEA Vapor System(TM)</intervention_name>
    <description>vapor endometrial ablation</description>
    <arm_group_label>vapor endometrial ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subject from (and including) age 30 to 50 years

          -  Self-reported history of heavy menstrual bleeding in at least 3 of the last 6 months

          -  Predictable cyclic menstrual cycles over past 6 months

          -  Excessive uterine bleeding

          -  Premenopausal at enrollment

          -  Normal PAP

          -  Normal endometrial biopsy

          -  Willing to use reliable contraception

          -  Not currently taking hormonal medication

          -  Agree to use sponsor provided catamenial product (sanitary pads/tampons)

        Exclusion Criteria:

          -  Pregnant

          -  Desires future childbearing

          -  Presence of an IUD

          -  Previous endometrial ablation procedure

          -  Evidence of STI

          -  Evidence of PID

          -  Active infection of genitals, vagina, cervix, uterus or urinary tract

          -  Active endometritis

          -  Active bacteremia, sepsis or other active systemic infection

          -  Gynecologic malignancy

          -  Endometrial hyperplasia

          -  Known clotting defects or bleeding disorders

          -  On anticoagulant therapy

          -  Hemoglobin &lt;8gm/dl

          -  Prior uterine surgery

          -  Currently on medication that could thin myometrial muscle

          -  Severe dysmenorrhea, secondary to adenomyosis

          -  Abnormal uterine cavity

          -  Hydrosalpinx

          -  Uterine length &lt;6cm or &gt;12cm

          -  Currently in other clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Levie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Connie A Rey</last_name>
    <phone>(650)218-7225</phone>
    <email>crey@aegeamedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ekta Wilcox</last_name>
    <phone>(248)624-7702</phone>
    <email>ektawilcox@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Fertility and Women's Health</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Lytton</last_name>
      <phone>860-224-5900</phone>
      <email>heidi.lytton@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>Anthony Luciano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Fenwick</last_name>
      <phone>561-964-7880</phone>
      <email>Sfenwick@atlanticclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Seth J Herbst, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Advanced Gynecologic Surgery Institute</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Johnston</last_name>
      <phone>630-364-1119</phone>
      <email>mjohnston@charlesmillermd.org</email>
    </contact>
    <investigator>
      <last_name>Charles E Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa J Beaudoin, RN, BSN</last_name>
      <phone>314-583-7473</phone>
      <email>tjbranca1@sbcglobal.net</email>
    </contact>
    <investigator>
      <last_name>David Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Magnan</last_name>
      <phone>718-405-8396</phone>
      <email>mmagnani@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Mark D Levie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Women's Research and Wellness Center/OB-GYN</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atiya Sherwani</last_name>
      <phone>919-251-9223</phone>
      <email>atiya@cwrwc.com</email>
    </contact>
    <investigator>
      <last_name>Andrea S Lukes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor All Saints</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Cheney</last_name>
      <phone>817-922-2579</phone>
      <email>theresa.cheyne@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Delbert A Johns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 21, 2014</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial ablation with vapor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
